Trial Profile
A Phase 2, Randomized, Multi-institutional Study of Nivolumab and Ipilimumab Versus Nivolumab, Ipilimumab and Stereotactic Body Radiation Therapy for Metastatic Merkel Cell Carcinoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 24 Sep 2023
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Merkel cell carcinoma
- Focus Therapeutic Use
- 13 Jul 2023 Planned End Date changed from 1 Jul 2023 to 1 Jul 2024.
- 13 Sep 2022 Results presented at the 47th European Society for Medical Oncology Congress
- 13 Sep 2022 Primary endpoint has not been met. (Objective Response Rate), as per Results published in the Lancet